Clinical Trials
Clinical Trials
DOORwaY-90 Study
*Using Common Terminology Criteria for Adverse Events v.5.0
BCLC, Barcelona Clinic Liver Cancer, ECOG, Easter Cooperative Oncology Group; EQ-5D-5L, EuroQoL 5-Dimensions 5-Level; FACT-Hep, Functional Assessment of Cancer Therapy-Hepatobiliary; HCC, hepatocellular carcinoma; LI-RADS, Liver Imaging Reporting And Data System; mRECIST, modified Response Evaluation Criteria in Solid Tumors; QoL, quality of life; SIRT, selective internal radiation therapy.
BCLC, Barcelona Clinic Liver Cancer, ECOG, Easter Cooperative Oncology Group; EQ-5D-5L, EuroQoL 5-Dimensions 5-Level; FACT-Hep, Functional Assessment of Cancer Therapy-Hepatobiliary; HCC, hepatocellular carcinoma; LI-RADS, Liver Imaging Reporting And Data System; mRECIST, modified Response Evaluation Criteria in Solid Tumors; QoL, quality of life; SIRT, selective internal radiation therapy.
Indications for Use: SIR-Spheres Y-90 resin microspheres are indicated for the treatment of unresectable metastatic liver tumors from primary colorectal cancer with adjuvant intrahepatic artery chemotherapy (IHAC) of FUDR (Floxuridine). Consult the Instructions for Use for a complete listing of indications, contraindications, side effects, warnings, and precautions.